MA28566B1 - PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES - Google Patents
PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASESInfo
- Publication number
- MA28566B1 MA28566B1 MA29430A MA29430A MA28566B1 MA 28566 B1 MA28566 B1 MA 28566B1 MA 29430 A MA29430 A MA 29430A MA 29430 A MA29430 A MA 29430A MA 28566 B1 MA28566 B1 MA 28566B1
- Authority
- MA
- Morocco
- Prior art keywords
- prostaglandin
- treatment
- receptor antagonists
- inflammatory diseases
- antagonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56041004P | 2004-04-07 | 2004-04-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA28566B1 true MA28566B1 (en) | 2007-05-02 |
Family
ID=34965223
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA29430A MA28566B1 (en) | 2004-04-07 | 2006-11-02 | PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES |
Country Status (21)
Country | Link |
---|---|
EP (1) | EP1740547A1 (en) |
JP (1) | JP2007532555A (en) |
KR (1) | KR20070002085A (en) |
CN (1) | CN101018770A (en) |
AR (1) | AR048528A1 (en) |
AU (1) | AU2005233125A1 (en) |
BR (1) | BRPI0509668A (en) |
CA (1) | CA2561564A1 (en) |
CL (1) | CL2008000069A1 (en) |
CR (1) | CR8659A (en) |
EC (1) | ECSP066977A (en) |
IL (1) | IL178328A0 (en) |
MA (1) | MA28566B1 (en) |
MX (1) | MXPA06011540A (en) |
NO (1) | NO20065107L (en) |
RU (1) | RU2006138603A (en) |
TN (1) | TNSN06320A1 (en) |
TW (1) | TW200538127A (en) |
UA (1) | UA84749C2 (en) |
WO (1) | WO2005100321A1 (en) |
ZA (1) | ZA200608955B (en) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0608553A2 (en) | 2005-02-24 | 2010-01-12 | Millennium Pharm Inc | pgd2 receptor antagonists for the treatment of inflammatory diseases |
EP1717235A3 (en) * | 2005-04-29 | 2007-02-28 | Bioprojet | Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands |
CA2616937A1 (en) | 2005-07-29 | 2007-02-08 | F. Hoffman-La Roche Ag | Indol-3-yl-carbonyl-piperidin and piperazin derivatives |
US9254293B2 (en) | 2006-06-16 | 2016-02-09 | The Trustees Of The University Of Pennsylvania | Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and BPH |
EP2086970B1 (en) | 2006-08-24 | 2014-02-26 | Novartis AG | 2-(pyrazin-2-yl)-thiazole and 2-(1h pyrazol-3-yl)-thiazole derivatives as well as related compounds as stearoyl-coa desaturase (scd) inhibitors for the treatment of metabolic, cardiovascular and other disorders |
JPWO2008029924A1 (en) | 2006-09-08 | 2010-01-21 | 大日本住友製薬株式会社 | Cyclic aminoalkylcarboxamide derivatives |
RU2009114857A (en) | 2006-09-22 | 2010-10-27 | Новартис АГ (CH) | HETEROCYCLIC ORGANIC COMPOUNDS |
EA200900820A1 (en) | 2006-12-20 | 2010-02-26 | Новартис Аг | 2-substituted 5-member heterocycles as stearaoyl-soa-desaturase inhibitors (SSDs) |
JP5466507B2 (en) | 2007-09-27 | 2014-04-09 | 興和株式会社 | A prophylactic and / or therapeutic agent for anemia comprising a tetrahydroquinoline compound as an active ingredient |
DK2327693T3 (en) | 2007-12-14 | 2012-08-13 | Pulmagen Therapeutics Asthma Ltd | Indoles and their therapeutic use |
JP2011102241A (en) * | 2008-03-04 | 2011-05-26 | Dainippon Sumitomo Pharma Co Ltd | Novel 1-aminocarbonylpiperidine derivative |
EP2328619B1 (en) | 2008-08-22 | 2016-12-07 | Baxalta GmbH | Polymeric benzyl carbonate-derivatives |
JP2011256110A (en) * | 2008-09-30 | 2011-12-22 | Takeda Chem Ind Ltd | Manufacturing method of hexahydropyrroloquinoline |
EP2415764A4 (en) | 2009-03-31 | 2012-08-08 | Kowa Co | Prophylactic and/or therapeutic agent for anemia comprising tetrahydroquinoline compound as active ingredient |
GB0919431D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
EP2955524A3 (en) | 2009-11-05 | 2016-03-23 | GlaxoSmithKline LLC | Novel process |
BR112013000254A2 (en) | 2010-07-05 | 2016-05-24 | Actelion Pharmaceuticals Ltd | 1-phenyl-substituted heterocyclic derivatives and their use as prostaglandin d2 receptor modulators |
EP2457900A1 (en) | 2010-11-25 | 2012-05-30 | Almirall, S.A. | New pyrazole derivatives having CRTh2 antagonistic behaviour |
WO2012174176A1 (en) | 2011-06-17 | 2012-12-20 | Merck Sharp & Dohme Corp. | Cycloalkyl-fused tetrahydroquinolines as crth2 receptor modulators |
UA112667C2 (en) | 2011-12-16 | 2016-10-10 | Атопікс Терапеутікс Лімітед | COMBINATION OF CRTH2 ANTAGONIST AND PROTON PUMP INHIBITOR FOR TREATMENT OF EOSINOPHILIC ESOPHAGITIS |
CN104011021B (en) | 2011-12-21 | 2016-08-24 | 埃科特莱茵药品有限公司 | Hete rocyclic derivatives and the purposes as prostaglandin D 2 receptor conditioning agent thereof |
WO2014006585A1 (en) | 2012-07-05 | 2014-01-09 | Actelion Pharmaceuticals Ltd | 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators |
JP2018530995A (en) | 2015-07-30 | 2018-10-25 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | Single nucleotide polymorphism allele of human DP-2 gene for detection of sensitivity to hair growth inhibition by PGD2 |
JOP20190105A1 (en) * | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | Magl inhibitors |
KR20210003160A (en) | 2018-04-18 | 2021-01-11 | 콘스텔레이션 파마슈티칼스, 인크. | Methyl modifying enzyme modulators, compositions and uses thereof |
CA3100977A1 (en) | 2018-05-21 | 2019-11-28 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
CN113201316B (en) * | 2021-04-25 | 2022-08-26 | 西南石油大学 | temperature/CO 2 pH multi-responsive emulsifier and emulsion and application thereof |
CN116425623B (en) * | 2023-04-10 | 2024-02-13 | 大连凯飞化学股份有限公司 | Method for synthesizing 3,5-dichloro-4-methylbenzoic acid by one-pot method |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE298747T1 (en) * | 1998-03-31 | 2005-07-15 | Shionogi & Co | METHOD FOR PRODUCING 5-HYDROXYBENZO(B)THIOPHEN-3-CARBONIC ACID |
CZ20032898A3 (en) * | 2001-04-30 | 2004-07-14 | Pfizer Products Inc. | Process for preparing CETP inhibitors |
JP2003321471A (en) * | 2002-04-30 | 2003-11-11 | Fuji Photo Film Co Ltd | Lactam compound and method of production for the same |
US20040053842A1 (en) * | 2002-07-02 | 2004-03-18 | Pfizer Inc. | Methods of treatment with CETP inhibitors and antihypertensive agents |
EP1556047A4 (en) * | 2002-10-04 | 2009-09-30 | Millennium Pharm Inc | Pgd2 receptor antagonists for the treatment of inflammatory diseases |
ES2263015T3 (en) * | 2002-10-21 | 2006-12-01 | Warner-Lambert Company Llc | TETRAHYDROQUINOLINE DERIVATIVES AS AN ANTHOGONIST OF CRTH2 |
WO2004052863A1 (en) * | 2002-12-06 | 2004-06-24 | Kyowa Hakko Kogyo Co., Ltd. | Anti-inflammatory agent |
EP1435356A1 (en) * | 2003-01-06 | 2004-07-07 | Warner-Lambert Company LLC | Quinoline derivatives as CRTH2 antagonists |
-
2005
- 2005-04-07 KR KR1020067023323A patent/KR20070002085A/en not_active Application Discontinuation
- 2005-04-07 MX MXPA06011540A patent/MXPA06011540A/en not_active Application Discontinuation
- 2005-04-07 WO PCT/US2005/011643 patent/WO2005100321A1/en active Application Filing
- 2005-04-07 RU RU2006138603/04A patent/RU2006138603A/en not_active Application Discontinuation
- 2005-04-07 AU AU2005233125A patent/AU2005233125A1/en not_active Withdrawn
- 2005-04-07 JP JP2007507467A patent/JP2007532555A/en active Pending
- 2005-04-07 UA UAA200611678A patent/UA84749C2/en unknown
- 2005-04-07 TW TW094111008A patent/TW200538127A/en unknown
- 2005-04-07 EP EP05733968A patent/EP1740547A1/en not_active Withdrawn
- 2005-04-07 CA CA002561564A patent/CA2561564A1/en not_active Abandoned
- 2005-04-07 BR BRPI0509668-5A patent/BRPI0509668A/en not_active IP Right Cessation
- 2005-04-07 CN CNA200580018590XA patent/CN101018770A/en active Pending
- 2005-04-07 AR ARP050101369A patent/AR048528A1/en unknown
-
2006
- 2006-09-27 IL IL178328A patent/IL178328A0/en unknown
- 2006-09-27 CR CR8659A patent/CR8659A/en not_active Application Discontinuation
- 2006-10-06 TN TNP2006000320A patent/TNSN06320A1/en unknown
- 2006-10-27 ZA ZA200608955A patent/ZA200608955B/en unknown
- 2006-11-02 MA MA29430A patent/MA28566B1/en unknown
- 2006-11-06 NO NO20065107A patent/NO20065107L/en not_active Application Discontinuation
- 2006-11-08 EC EC2006006977A patent/ECSP066977A/en unknown
-
2008
- 2008-01-10 CL CL200800069A patent/CL2008000069A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
RU2006138603A (en) | 2008-05-20 |
JP2007532555A (en) | 2007-11-15 |
MXPA06011540A (en) | 2007-01-26 |
KR20070002085A (en) | 2007-01-04 |
ZA200608955B (en) | 2009-05-27 |
TW200538127A (en) | 2005-12-01 |
CN101018770A (en) | 2007-08-15 |
ECSP066977A (en) | 2006-12-29 |
UA84749C2 (en) | 2008-11-25 |
BRPI0509668A (en) | 2007-10-09 |
AR048528A1 (en) | 2006-05-03 |
CR8659A (en) | 2007-06-08 |
EP1740547A1 (en) | 2007-01-10 |
AU2005233125A1 (en) | 2005-10-27 |
WO2005100321A1 (en) | 2005-10-27 |
CL2008000069A1 (en) | 2008-05-16 |
IL178328A0 (en) | 2007-02-11 |
CA2561564A1 (en) | 2005-10-27 |
TNSN06320A1 (en) | 2008-02-22 |
NO20065107L (en) | 2006-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA28566B1 (en) | PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | |
ZA200707498B (en) | PGD2 receptor antagonists for the treatment of inflammatory diseases | |
PL376156A1 (en) | Pgd2 receptor antagonists for the treatment of inflammatory diseases | |
CY2017039I1 (en) | HIGH-AFFINITY ANTIBODIES TO THE HUMAN IL-6 RECEPTOR | |
MA29071B1 (en) | 2, 6-SUBSTITUTED-4-MONOSUBSTITUTED AMINO-PYRIDIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | |
FR20C1014I2 (en) | TREATMENT OF SLEEP-WAKE CYCLE DISORDERS | |
FR15C0046I2 (en) | DRUGS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | |
NO20054343D0 (en) | Treatment of immunological disorders using agonists of interleukin-21 / interleukin-21 receptor | |
FR15C0048I2 (en) | IL-17 ANTAGONIST ANTIBODIES | |
MA28871B1 (en) | ACCURATE TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | |
SMT201700014B (en) | THERAPEUTIC AGENTS FOR THE REDUCTION OF LEVELS OF PARATIROIDOUS HORMONE | |
MA28791B1 (en) | PIPERAZINE DERIVATIVES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | |
DK1729753T3 (en) | Use of an NMDA Receptor Antagonist to Treat Tinnitus Induced by Cochlear Excitotoxicity | |
MA28555B1 (en) | SUBSTITUTED MORPHOLINE DERIVATIVES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | |
DE60309913D1 (en) | BICYCLIC BENZAMIDE COMPOUNDS AS HISTAMINE H3 RECEPTOR LIGANDS SUITABLE FOR THE TREATMENT OF NEUROLOGICAL DISEASES | |
ATE478864T1 (en) | HYDANTOINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | |
EP1807391A4 (en) | Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases | |
BRPI0912362A2 (en) | nmda receptor antagonist for the treatment of neuropsychiatric disorders | |
EP1940800A4 (en) | Novel bicyclic sulfonamides for use as glucocorticoid receptor modulators in the treatment of inflammatory diseases | |
IL182365A0 (en) | 5-sulfonyl-1-piperidinyl substituted indole derivatives as 5-ht6 receptor antagonists for the treatment of cns disorders | |
HK1098155A1 (en) | Nicotinic receptor agonists for the treatment of inflammatory diseases | |
FR2887141B1 (en) | COMPRESSIVE ORTHESIS TRICOTEE OF THE LOWER MEMBER FOR THE TREATMENT OF CHRONIC VENOUS INSUFFICIENCY | |
ATE465150T1 (en) | PIPERAZINYL DERIVATIVES SUITABLE FOR THE TREATMENT OF DISEASES MEDIATED BY THE GPR38 RECEPTOR | |
IL182424A0 (en) | Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases | |
CY2013037I2 (en) | ANTAGONIST II RECEPTOR ANTAGONIST FOR THE THERAPEUTIC TREATMENT OF SYSTEMIC DISEASE IN CATS |